GSK plc Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights - GSK

Core Viewpoint - GSK plc is facing allegations related to misleading statements about the safety of Zantac, which may have led to investor losses during the specified class period from February 5, 2020, to August 14, 2022 [1] Group 1: Allegations and Legal Context - The complaint alleges that GSK misrepresented the reasons for withdrawing Zantac from the market, claiming it was based on available information and regulatory correspondence, while being aware of the source of NDMA for nearly 40 years [1] - GSK assured investors that there was no causal link between ranitidine therapy and cancer, which the complaint argues was materially false or misleading [1] - The company claimed it could not quantify or reliably estimate its liability, which is also contested in the allegations [1] Group 2: Shareholder Actions and Deadlines - Shareholders who purchased GSK shares during the class period are encouraged to register for the class action, with a deadline of April 7, 2025, to seek lead plaintiff status [2] - Registered shareholders will receive updates through portfolio monitoring software regarding the case's progress [2] Group 3: Law Firm's Mission and Commitment - The Gross Law Firm aims to protect investors' rights against deceit and fraud, emphasizing the importance of responsible business practices [3] - The firm seeks recovery for investors who suffered losses due to misleading statements that inflated GSK's stock price [3]